Circulating free tumor DNA and colorectal cancer.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Gastroentérologie Clinique et Biologique

• Publication date

  2010-12-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.gcb.2009.04.015PMID 20832215
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The hallmarks of cancer

  2012cited by this paper
• KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

  2008cited by this paper
• Clinical interest of KRAS mutation detection in blood for anti-EGFR therapies in metastatic colorectal cancer

  2008cited by this paper
• Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer.

  2008cited by this paper
• Circulating mutant DNA to assess tumor dynamics

  2008cited by this paper
• Mutations de l’ADN mitochondrial et cancer colorectal

  2008cited by this paper
• Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients.

  2008cited by this paper
• Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

  2007cited by this paper
• Towards Clinical Application of Methylated DNA Sequences as Cancer Biomarkers: A Joint NCI's EDRN and NIST Workshop on Standards, Methods, Assays, Reagents and Tools.

  2007cited by this paper
• Free circulating DNA as possible tumour marker in colorectal cancer.

  2007cited by this paper
• DNA Methylation in Colorectal cancer—Impact on Screening and Therapy Monitoring Modalities?

  2007cited by this paper
• Circulating nucleic acids (CNAs) and cancer--a survey.

  2007cited by this paper
• Free DNA and Carcinoembryonic Antigen Serum Levels: An Important Combination for Diagnosis of Colorectal Cancer

  2006cited by this paper
• Molecular detection of TP53, Ki-Ras and p16INK4A promoter methylation in plasma of patients with colorectal cancer and its association with prognosis. Results of a 3-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study.

  2006cited by this paper
• Agreement between K-ras sequence variations detected in plasma and tissue DNA in pancreatic and colorectal cancer.

  2006cited by this paper
• Aristaless-like homeobox-4 gene methylation is a potential marker for colorectal adenocarcinomas.

  2006cited by this paper
• Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats.

  2006cited by this paper
• Prediction of breast tumor progression by integrity of free circulating DNA in serum.

  2006cited by this paper
• Methylation of Serum DNA Is an Independent Prognostic Marker in Colorectal Cancer

  2006cited by this paper
• Comparative Analysis of Mesenteric and Peripheral Blood Circulating Tumor DNA in Colorectal Cancer Patients

  2006cited by this paper
• Molecular Screening of Cancer

  2006cited by this paper
• Detection and quantification of mutations in the plasma of patients with colorectal tumors.

  2005cited by this paper
• Quantitative Detection of Promoter Hypermethylation in Multiple Genes in the Serum of Patients with Colorectal Cancer

  2005cited by this paper
• Systemic therapy for colorectal cancer.

  2005cited by this paper
• Evolution of intratumoral genetic heterogeneity during colorectal cancer progression.

  2005cited by this paper
• [Mitochondrial DNA mutations and colorectal cancer].

  2005cited by this paper
• Somatic evolution of cancer cells.

  2005cited by this paper
• Urological Survey UROLOGICAL ONCOLOGY: RENAL, URETERAL AND RETROPERITONEAL TUMORS Quantitative Detection of Promoter Hypermethylation of Multiple Genes in the Tumor, Urine, and Serum DNA of Patients With Renal Cancer

  2005cited by this paper
• APC, K-ras, and p53 Gene Mutations in Colorectal Cancer Patients: Correlation to Clinicopathologic Features and Postoperative Surveillance

  2005cited by this paper
• The effect of inflammation on the generation of plasma DNA from dead and dying cells in the peritoneum

  2005cited by this paper
• Persistence of K-ras mutations in plasma after colorectal tumor resection.

  2005cited by this paper
• High Sensitivity Scanning of Colorectal Tumors and Matched Plasma DNA for Mutations in APC, TP53, K‐RAS, and BRAF Genes with a Novel DHPLC Fluorescence Detection Platform

  2004cited by this paper
• Circulating deoxyribonucleic Acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy.

  2004cited by this paper
• NUCLEOSIDES, NUCLEOTIDES & NUCLEIC ACIDS

  2004cited by this paper
• Molecular Detection of APC, K-ras, and p53 Mutations in the Serum of Colorectal Cancer Patients as Circulating Biomarkers

  2004cited by this paper
• Cancer colorectal : altérations moléculaires pronostiques

  2004cited by this paper
• [Colorectal cancer: prognostic molecular markers].

  2004cited by this paper
• Amount of DNA in plasma and cancer risk: A prospective study

  2004cited by this paper
• Circulating nucleic acids in plasma and serum (CNAPS) and its relation to stem cells and cancer metastasis: state of the issue.

  2004cited by this paper
• Preferential isolation of fragmented DNA enhances the detection of circulating mutated k-ras DNA.

  2004cited by this paper
• Detection of Circulating Tumour DNA in the Blood (Plasma/Serum) of Cancer Patients

  2004cited by this paper
• Increased concentrations of cell-free plasma DNA after exhaustive exercise.

  2004cited by this paper
• Molecular detection of p16 promoter methylation in the serum of recurrent colorectal cancer patients

  2003cited by this paper
• DNA integrity as a potential marker for stool-based detection of colorectal cancer.

  2003cited by this paper
• Increased plasma DNA integrity in cancer patients.

  2003cited by this paper
• The study of p16 and p15 gene methylation in head and neck squamous cell carcinoma and their quantitative evaluation in plasma by real-time PCR.

  2003cited by this paper
• Genetic heterogeneity in lung and colorectal carcinoma as revealed by microsatellite analysis in plasma or tumor tissue DNA

  2003cited by this paper
• High frequency of DAP-kinase gene promoter methylation in colorectal cancer specimens and its identification in serum.

  2003cited by this paper
• TP53 and mutations in human cancer.

  2003cited by this paper
• Clinical significance in molecular detection of p53 mutation in serum of patients with colorectal carcinoma.

  2003cited by this paper
• A prospective study of circulating mutant KRAS2 in the serum of patients with colorectal neoplasia: strong prognostic indicator in postoperative follow up

  2003cited by this paper
• Quantitative analysis of tumor-derived methylated p16INK4a sequences in plasma, serum, and blood cells of hepatocellular carcinoma patients.

  2003cited by this paper
• Cell-free DNA: measurement in various carcinomas and establishment of normal reference range.

  2002cited by this paper
• K- ras Mutations in Sera of Patients with Colorectal Neoplasias and Long-standing Inflammatory Bowel Disease

  2002cited by this paper
• DNA methylation patterns and epigenetic memory.

  2002cited by this paper
• Difference between free circulating plasma and serum DNA in patients with colorectal liver metastases.

  2002cited by this paper
• Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status

  2002cited by this paper
• Detection of Tumor DNA in Serum of Colorectal Cancer Patients

  2002cited by this paper
• Detection of aberrant p16 methylation in the serum of colorectal cancer patients.

  2002cited by this paper
• Detection of free‐circulating tumor‐associated DNA in plasma of colorectal cancer patients and its association with prognosis

  2002cited by this paper
• Molecular detection of p16 promoter methylation in the serum of colorectal cancer patients.

  2002cited by this paper
• Mutations of the BRAF gene in human cancer

  2002cited by this paper
• DNA methylation and breast carcinogenesis

  2002cited by this paper
• Mutations in APC, Kirsten-ras, and p53—alternative genetic pathways to colorectal cancer

  2002cited by this paper
• Difference between free circulating plasma and serum DNA in patients with colorectal liver metastases.

  2002cited by this paper
• Microsatellite instability and intratumoural heterogeneity in 100 right-sided sporadic colon carcinomas

  2002cited by this paper
• Detection of APC and k-ras mutations in the serum of patients with colorectal cancer.

  2001cited by this paper
• DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells.

  2001cited by this paper
• Methylation and colorectal cancer

  2001cited by this paper
• Detection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer.

  2001cited by this paper
• Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study

  2001cited by this paper
• The ABC of APC.

  2001cited by this paper
• Intratumor genetic heterogeneity in advanced human colorectal adenocarcinoma

  2001cited by this paper
• About the possible origin and mechanism of circulating DNA apoptosis and active DNA release.

  2001cited by this paper
• Heterogeneous tumor clones as an explanation of discordance between plasma DNA and tumor DNA alterations

  2001cited by this paper
• Functionality of circulating DNA: the hypothesis of genometastasis.

  2001cited by this paper
• Genetic alterations in bronchial mucosa and plasma DNA from individuals at high risk of lung cancer

  2001cited by this paper
• Detection of mitochondrial DNA alterations in primary tumors and corresponding serum of colorectal cancer patients

  2001cited by this paper
• Functionality of Circulating DNA

  2001cited by this paper
• Molecular Detection of Codon 12 K-RAS Mutations in Circulating DNA from Serum of Colorectal Cancer Patients

  2000cited by this paper
• Molecular testing of urine: catching DNA on the way out.

  2000cited by this paper
• Somatic mutation screening: identification of individuals harboring K-ras mutations with the use of plasma DNA.

  2000cited by this paper
• p53 and APC Mutations Are Detectable in the Plasma and Serum of Patients with Colorectal Cancer (CRC) or Adenomas

  2000cited by this paper
• Factors Influencing the Detection of Mutant K‐ras in the Serum of Patients with Colorectal Cancer

  2000cited by this paper
• Cellular‐ versus Extracellular‐Based Assays: Comparing Utility in DNA and RNA Molecular Marker Assessment

  2000cited by this paper
• Detection of plasma tumor DNA in head and neck squamous cell carcinoma by microsatellite typing and p53 mutation analysis.

  2000cited by this paper
• Plasma DNA as a prognostic marker in trauma patients.

  2000cited by this paper
• Detection of tumor mutant APC DNA in plasma of patients with sporadic colorectal cancer.

  2000cited by this paper
• Serum Mutant K‐ras in the Colorectal Adenoma‐to‐Carcinoma Sequence: Implications for Diagnosis, Postoperative Follow‐up, and Early Detection of Recurrent Disease

  2000cited by this paper
• Plasma DNA K‐ras Mutations in Patients with Gastrointestinal Malignancies

  2000cited by this paper
• Genetic analysis of DNA excreted in urine: a new approach for detecting specific genomic DNA sequences from cells dying in an organism.

  2000cited by this paper
• Detection of mutated KRAS2 sequences as tumor markers in plasma/serum of patients with gastrointestinal cancer.

  2000cited by this paper
• PCR artifacts in LOH and MSI analysis of microdissected tumor cells.

  2000cited by this paper
• Quantitative analysis of aberrant p16 methylation using real-time quantitative methylation-specific polymerase chain reaction.

  1999cited by this paper
• Rapid clearance of fetal DNA from maternal plasma.

  1999cited by this paper
• Microsatellite alterations in serum DNA of patients with colorectal cancer.

  1999cited by this paper
• Detecting tumor-related alterations in plasma or serum DNA of patients diagnosed with breast cancer.

  1999cited by this paper
• K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance.

  1999cited by this paper
• Mitochondrial mutagenesis in human cells and tissues.

  1999cited by this paper
• Mutations of p53 gene can be detected in the plasma of patients with large bowel carcinoma.

  1998cited by this paper

• Early Detection of Pancreatic and Colorectal Cancers via Ultra-Sensitive Circulating Tumor DNA (ctDNA) Analysis

  2025cites this paper
• Analyzing microsatellite instability and gene mutation in circulating cell-free DNA to monitor colorectal cancer progression

  2021cites this paper
• Tracking the Antibody Immunome in Sporadic Colorectal Cancer by Using Antigen Self-Assembled Protein Arrays

  2021cites this paper
• Detection of Colorectal Cancer and Advanced Adenoma by Liquid Biopsy (Decalib Study): The ddPCR Challenge

  2020cites this paper
• Non-invasive genotyping of metastatic colorectal cancer using circulating cell free DNA.

  2019cites this paper
• Developing a blood-based gene mutation assay as a novel biomarker for oesophageal adenocarcinoma

  2019cites this paper
• The Clinical Landscape of Circulating Tumor DNA in Gastrointestinal Malignancies

  2018cites this paper
• Liquid Biopsy in Colorectal Cancer-Current Status and Potential Clinical Applications

  2018cites this paper
• Emerging Concepts in Liquid Biopsy

  2018cites this paper
• The prognostic value of simultaneous tumor and serum RAS/RAF mutations in localized colon cancer

  2017cites this paper
• Advancements in next-generation sequencing for diagnosis and treatment of non-small-cell lung cancer

  2017cites this paper
• The clinical role of circulating free tumor DNA in gastrointestinal malignancy

  2017cites this paper
• Hypomethylated Ubiquitin-Conjugating Enzyme2 Q1 (UBE2Q1) Gene Promoter in the Serum Is a Promising Biomarker for Hepatitis B Virus-Associated Hepatocellular Carcinoma.

  2017cites this paper
• Place de l’ ADN tumoral circulant dans la prise en charge des patients atteints d’une tumeur pulmonaire : impact pronostique et suivi dynamique de l’évolution des altérations génétiques au cours du traitement

  2017cites this paper
• Comparative Study of Mutations in Single Nucleotide Polymorphism Loci of KRAS and BRAF Genes in Patients Who Underwent Screening Colonoscopy, With and Without Premalignant Intestinal Polyps.

  2017cites this paper
• Circulating Tumor DNA is Effective for Detection of KRAS Mutation in Colorectal Cancer: A Meta-Analysis

  2017cites this paper
• Cell‐free DNA results lead to unexpected diagnosis

  2017cites this paper
• Circulating tumor cells and circulating tumor DNA in colon cancer

  2016cites this paper
• Role of specific DNA mutations in the peripheral blood of colorectal cancer patients for the assessment of tumor stage and residual disease following tumor resection

  2016cites this paper
• Next-Generation Sequencing and Applications to the Diagnosis and Treatment of Lung Cancer.

  2016cites this paper
• The clinical role of 'liquid biopsy' in hepatocellular carcinoma.

  2016cites this paper
• Monitoring KRAS mutations in circulating DNA and tumor cells using digital droplet PCR during treatment of KRAS-mutated lung adenocarcinoma.

  2016cites this paper
• Biomarkers in Metastatic Colorectal Cancer

  2015cites this paper
• Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? A report of the association for molecular pathology.

  2015cites this paper
• Assessment of DNA Integrity, Applications for Cancer Research.

  2015cites this paper
• Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer

  2015cites this paper
• Circulating DNA in Cancer: An Overview

  2015cites this paper
• "Liquid biopsy"-ctDNA detection with great potential and challenges.

  2015cites this paper
• Do Circulating Tumor Cells, Exosomes, and Circulating Tumor Nucleic Acids Have Clinical Utility?: A Report of the Association for Molecular Pathology.

  2015cites this paper
• Biomarkers in Metastatic Colorectal Cancer: Predicting Prognosis and Therapeutic Response

  2014cites this paper
• Clinical Relevance of Alterations in Quantity and Quality of Plasma DNA in Colorectal Cancer Patients: Based on the Mutation Spectra Detected in Primary Tumors

  2014cites this paper
• Circulating Free DNA in a Screening Program for Early Colorectal Cancer Detection

  2014cites this paper
• Comparison of KRAS mutation analysis of primary tumors and matched circulating cell-free DNA in plasmas of patients with colorectal cancer.

  2014cites this paper
• Microsatellite instability typing in serum and tissue of patients with colorectal cancer: comparing real time PCR with hybridization probe and high-performance liquid chromatography

  2014influential citation
• Alternatives for the Intensive Follow-Up After Curative Resection of Colorectal Cancer. Potential Novel Biomarkers for the Recommendations

  2013cites this paper
• Multiplex picoliter-droplet digital PCR for quantitative assessment of DNA integrity in clinical samples.

  2013cites this paper
• Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: Outcome and results of KRAS mutational analysis in plasma

  2013cites this paper
• Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations.

  2013cites this paper
• BEAMing and Droplet Digital PCR Analysis of Mutant IDH1 mRNA in Glioma Patient Serum and Cerebrospinal Fluid Extracellular Vesicles

  2013cites this paper
• Cell-free DNA concentration and integrity as a screening tool for cancer.

  2013cites this paper
• Predicting chemotherapeutic response and toxicity in colorectal cancer

  2013cites this paper
• Circulating DNA, digital PCR and colorectal cancers.

  2013cites this paper
• Circulating nucleic acids in plasma and serum (CNAPS): applications in oncology

  2013influential citation
• Cell-free DNA: characteristics, detection and its applications in myocardial infarction.

  2013cites this paper
• Comparison of KRAS Mutation Assessment in Tumor DNA and Circulating Free DNA in Plasma and Serum Samples

  2012cites this paper
• Circulating cell-free nucleic acids: promising biomarkers of hepatocellular carcinoma.

  2012cites this paper
• Value of circulating DNA concentration and integrity as a screening test for detection of cancer in an Egyptian cohort

  2012cites this paper
• Oncogenic transformation induced by cell-free nucleic acids circulating in plasma (genometastasis) remains after the surgical resection of the primary tumor: a pilot study

  2012influential citation
• NIH-3T3 fibroblasts cultured with plasma from colorectal cancer patients generate poorly differentiated carcinomas in mice.

  2012cites this paper
• Quantitative Cell-Free DNA, KRAS, and BRAF Mutations in Plasma from Patients with Metastatic Colorectal Cancer during Treatment with Cetuximab and Irinotecan

  2012cites this paper
• Anti-epithelial cell adhesion molecule monoclonal antibody conjugated fluorescent nanoparticle biosensor for sensitive detection of colon cancer cells.

  2012cites this paper
• Les promesses de l’ADN circulant pour le pronostic du cancer colorectal

  2011cites this paper
• Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis.

  2011cites this paper
• Circulating free DNA: a new surrogate marker for minimal residual disease?

  2011cites this paper
• Quantitative and sensitive detection of rare mutations using droplet-based microfluidics.

  2011cites this paper
• Detection and clinical significance of DLC1 gene methylation in serum DNA from colorectal cancer patients

  2011cites this paper
• EMINAR irculating free tumor DNA and colorectal cancer

  2010cites this paper